Calidad de servicio en los usuarios de la banca digital de Chimbote, 2022

El objetivo de esta investigación fue determinar el nivel de calidad de servicio en los usuarios de la banca digital de Chimbote, 2022. La investigación fue de tipo aplicada, enfoque cuantitativo, nivel descriptivo, no experimental con una muestra de 383 clientes en línea de entidades bancarias, la técnica empleada para recolectar los datos fue la encuesta, el instrumento el cuestionario. Los resultados revelaron que la calidad de servicio es valorada con un nivel alto (55.1%) con inclinación a medio, en la perspectiva de los usuarios de la banca digital. Es decir, los usuarios aprecian que el servicio bancario digital otorga respuestas claras, es seguro, hay un buen trato, el personal es eficiente, entre otros aspectos de buena calidad. Asimismo, el 43.1% lo percibe como medio y tan solo el 1.8% de usuarios lo percibe como bajo. En conclusión, los usuarios evalúan al servicio de la banca digital como un nivel alto, según su percepción, la dimensión empatía fue la única dimensión evaluada con un nivel medio por lo que se sugirió motivar a sus clientes a través de incentivos, estos incentivos pueden ser, por ejemplo, bonos para clientes que hacen alguna operación particular por la banca digita

Neurocognitive profile of the post-COVID condition in adults in Catalonia. A mixed method prospective cohort and nested case-control study: Study Protocol

The diagnosis of the post-COVID condition is usually achieved by excluding other diseases; however, cognitive changes are often found in the post-COVID disorder. Therefore, monitoring and treating the recovery from the post-COVID condition is necessary to establish biomarkers to guide the diagnosis of symptoms, including cognitive impairment. Our study employs a prospected cohort and nested case-control design with mixed methods, including statistical analyses, interviews, and focus groups. Our main aim is to identify biomarkers (functional and structural neural changes, inflammatory and immune status, vascular and vestibular signs and symptoms) easily applied in primary care to detect cognitive changes in post-COVID cases. The results will open up a new line of research to inform diagnostic and therapeutic decisions with special considerations for cognitive impairment in the post-COVID condition

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

Breaking Yum and Lee Generic Constructions of Certificate-Less and Certificate-Based Encryption Schemes

Item does not contain fulltex

Utilization of Compatible Technology International (CTI) Grinders for Sorghum Flour Production in Central America

Slides discussing efforts by the Centro Nacionál de Tecnología Agropecuaria y Forestal (CENTA) to raise awareness of sorghum products and technologies. Programs highlighted include CENTA\u27s collaboration with the Foundation for International Medical Relief of Children (FIRMC) Nutritional Program, and the progress in the distribution and use of sorghum grinders in El Salvador

Wildmeat consumption and child health in Amazonia

Consuming wildmeat may protect against iron-deficiency anemia, a serious public health problem globally. Contributing to debates on the linkages between wildmeat and the health of forest-proximate people, we investigate whether wildmeat consumption is associated with hemoglobin concentration in rural and urban children (< 5 years old) in central Brazilian Amazonia. Because dietary practices mediate the potential nutritional benefits of wildmeat, we also examined whether its introduction into children’s diets is influenced by rural/urban location or household socio-economic characteristics. Sampling 610 children, we found that wildmeat consumption is associated with higher hemoglobin concentration among the rural children most vulnerable to poverty, but not in the least vulnerable rural, or urban children. Rural caregivers share wildmeat with children earlier-in-life than urban caregivers, potentially because of cultural differences, lower access to domesticated meat, and higher wildmeat consumption by rural households (four times the urban average). If wildmeat becomes unavailable through stricter regulations or over-harvesting, we predict a ~ 10% increased prevalence of anemia among extremely poor rural children. This modest protective effect indicates that ensuring wildmeat access is, alone, insufficient to control anemia. Sustainable wildlife management could enhance the nutritional benefits of wildlife for vulnerable Amazonians, but reducing multidimensional poverty and improving access to quality healthcare are paramount

Trichomonicidal activity of Maytenus imbricata (Celastraceae).

Trichomoniasis, most common non-viral sexually transmitted infection worldwide, is produced by protozoan Trichomonas vaginalis. The therapy of choice is metronidazole (MTZ). The drug has undesirable side effects, which may result in treatment discontinuation, leading to further spread of infection and emergence of resistant strains. This feature highlights the importance of studying new trichomonicidal substances. In this context, the importance of plants in relation to the research of new drugs is undeniable. The genus Maytenus, distributed throughout Brazil, is the largest of family Celastraceae, including about 80 recognized species with different biological activities. Therefore, the trichomonicidal activity of MTZ and extracts obtained from Maytenus robusta leaves and Maytenus imbricata roots on the JT strain of T. vaginalis, sensitive (JT) and resistant (JTR) to MTZ was investigated. Sample of T. vaginalis trophozoites were associated with extracts in 6 increasing concentrations ranging from 0.43 to 13.76 μg/ml. The solid that precipitated from the hexane/ethyl ether - 1:1 extract (SEH), obtained from M. imbricata roots proved to be active. This extract also impacted the viability of trophozoites of both strains, with IC50 value surprisingly low (1.09 μg/ml for JT and 1.57 μg/ml for JTR) signaling towards a promising candidate for phytotherapy or for isolation of substance with trichomonicidal activity

A new heterologous fibrin sealant as scaffold to recombinant human bone morphogenetic protein-2 (rhBMP-2) and natural latex proteins for the repair of tibial bone defects

Tissue engineering has special interest in bone tissue aiming at future medical applications Studies have focused on recombinant human bone morphogenetic protein-2 (rhBMP-2) and natural latex proteins due to the osteogenic properties of rhBMP-2 and the angiogenic characteristic of fraction 1 protein (P-1) extracted from the rubber tree Hevea brasiliensis. Furthermore, heterologous fibrin sealant (FS) has been shown as a promising alternative in regenerative therapies. The aim of this study was to evaluate these substances for the repair of bone defects in rats. A bone defect measuring 3 mm in diameter was created in the proximal metaphysis of the left tibia of 60 rats and was implanted with rhBMP-2 or P-1 in combination with a new heterologous FS derived from snake venom. The animals were divided into six groups: control (unfilled bone defect), rhBMP-2 (defect filled with 5 mu g rhBMP-2), P-1 (defect filled with 5 mu g P-1), FS (defect filled with 8 mu g FS), FS/rhBMP-2 (defect filled with 8 mu g FS and 5 mu g rhBMP-2), FS/P-1 (defect filled with 8 mu g FS and 5 mu g P-1). The animals were sacrificed 2 and 6 weeks after surgery. The newly formed bone projected from the margins of the original bone and exhibited trabecular morphology and a disorganized arrangement of osteocyte lacunae. Immunohistochemical analysis showed intense expression of osteocalcin in all groups. Histometric analysis revealed a significant difference in all groups after 2 weeks (p &lt; 0.05), except for the rhBMP-2 and FS/rhBMP-2 groups (p &gt; 0.05). A statistically significant difference (p &lt; 0.05) was observed in all groups after 6 weeks in relation to the volume of newly formed bone in the surgical area. In conclusion, the new heterologous fibrin sealant was found to be biocompatible and the combination with rhBMP-2 showed the highest osteogenic and osteoconductive capacity for bone healing. These findings suggest a promising application of this combination in the regeneration surgery